| Cohort, n = 46 | VFG+, n = 18 (39.1%) | VFG−, n = 28 (60.9%) | p-value |
---|---|---|---|---|
Revision surgery | 0.116 | |||
 n = 0 | 19 (41.3%) | 10 (55.6%) | 9 (32.1%) |  |
 n = 1; 2 | 15 (32.6%) | 5 (27.8%) | 10 (35.8%) |  |
 n ≥ 3 | 12 (26.1%) | 3 (16.6%) | 9 (32.1%) |  |
Allograft resorption (ISOLS) | 0.032 | |||
 1, excellent; 2, good | 39 (84.8%) | 18 (100%) | 21 (75.0%) |  |
 3, fair; 4, poor | 7 (15.2%) | 0 (0.0%) | 7 (25.0%) |  |
Complications | Â | |||
 Henderson 1 | 1 (2.2%) | 1 (5.6%) | 0 (0.0%) | 0.391 |
 Henderson 2 | 17 (37.0%) | 6 (33.3%) | 11 (39.3%) | 0.683 |
 Henderson 3 | 9 (19.6%) | 2 (11.1%) | 7 (25%) | 0.448 |
 Henderson 4 | 3 (6.5%) | 1 (5.6%) | 2 (7.1%) | 1 |
 Allograft removala | 2 (4.3%) | 1 (5.6%) | 1 (3.6%) | 1 |
Bone union | Â | Â | ||
 Healed at last follow-up | 43 (93.5%) | 17 (94.4%) | 26 (92.9%) | 1 |
 Healed with no revision | 28 (60.9%) | 12 (66.7%) | 16 (57.1%) | 0.578 |
 Mean bone union delay (months) | 21.8 (4–120) | 12.6 (5–34) | 27.9 (5–120) | 0.012 |
Functional score | Â | |||
 MSTS (/30) (n = 44) | 27.3 (18–30) | 26.3 (21–30) | 28 (18–30) | 0.060 |